Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Resources Pharma Files for $1 Billion IPO in Hong Kong

publication date: Jun 29, 2016
China Resources Pharmaceutical Group, China's second largest pharma, filed for a Hong Kong IPO that will raise at least $1 billion. It is planned for Q3 of this year. Based in Beijing, CR Pharma has a broad range of offerings in China and is also a major distributor of pharmaceuticals and general healthcare products. According to media reports, there are five China pharmas that are planning Hong Kong IPOs this year with an expected transaction total of $5 billion. Only Simcere Pharma, which was privatized from its US listing three years ago, was mentioned as part of that group. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital